{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"description":"Overall response rate was assessed according to Immune-related Response Criteria (irRC) (Wolchok, Hoos et al. 2009). ORR is the number of participants with a best overall response of irCR or irPR.\n\nirCR is defined as complete disappearance of all lesions with no new lesions; irPR as a ≥50% decrease in tumor burden from baseline; both are confirmed ≥4 weeks after initial documentation.\n\nOnly participants with adequate irRC tumor assessments (baseline and ≥1 post-baseline) and without major protocol deviations, were included in the analysis.","groups":[{"description":"Participants received 0.2 or 0.25 mg of Pegilodecakin QD administered SC along with Platinum/Taxane combination on Day 1 of each 21-day cycle for a maximum of 5 or 6 cycles. Participants received:\n\nPaclitaxel 200 or 175 mg/m² intravenously (IV) over 3 hours, or docetaxel 75 or 65 mg/m² IV over 1 hour, followed by carboplatin (AUC 6/5/4; max 6 × 150 mg) IV over 30 minutes or cisplatin 75 mg/m² IV over 6-8 hours.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG000","title":"Part B: Pegilodecakin 0.2/0.25 mg + Platinum/Taxane"},{"description":"Participants received 0.4 or 0.5 mg of Pegilodecakin QD administered SC along with Platinum/Taxane combination on Day 1 of each 21-day cycle for a maximum of 5 or 6 cycles. Participants received:\n\nPaclitaxel 200 or 175 mg/m² intravenously (IV) over 3 hours, or docetaxel 75 or 65 mg/m² IV over 1 hour, followed by carboplatin (AUC 6/5/4; max 6 × 150 mg) IV over 30 minutes or cisplatin 75 mg/m² IV over 6-8 hours.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG001","title":"Part B: Pegilodecakin 0.4/0.5 mg + Platinum/Taxane"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC along with Platinum/Taxane combination on Day 1 of each 21-day cycle for a maximum of 5 or 6 cycles. Participants received:\n\nPaclitaxel 200 or 175 mg/m² intravenously (IV) over 3 hours, or docetaxel 75 or 65 mg/m² IV over 1 hour, followed by carboplatin (AUC 6/5/4; max 6 × 150 mg) IV over 30 minutes or cisplatin 75 mg/m² IV over 6-8 hours.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG002","title":"Part B: Pegilodecakin 0.8/1 mg + Platinum/Taxane"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who received at least one dose of study intervention(s) and had an adequate irRC tumor assessment were included in the analysis.","reportingStatus":"POSTED","timeFrame":"From Date of First Dose of Study Drug until Disease Progression or Death (Up to 11 months)","title":"Part B: Number of Participants With Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Participants"}